Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis

Proteomics - Clinical Applications

Volumn 7, Issue 9-10, 2013, Pages 648-656

  Kamada, Yoshihiro ^a   Fujii, Hideki ^b   Fujii, Hironobu ^a   Sawai, Yoshiyuki ^c   Doi, Yoshinori ^d   Uozumi, Naofumi ^a,e   Mizutani, Kayo ^a   Akita, Maaya ^a   Sato, Motoya ^a   Kida, Sachiho ^a   Kinoshita, Noriaki ^f   Maruyama, Nobuhiro ^f   Yakushijin, Takayuki ^a   Miyazaki, Masanori ^a   Ezaki, Hisao ^a   Hiramatsu, Naoki ^a   Yoshida, Yuichi ^a   Kiso, Shinichi ^a   Imai, Yasuharu ^c   Kawada, Norifumi ^b   Takehara, Tetsuo ^a   Miyoshi, Eiji ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Ikeda Municipal Hospital   (Japan)

^d OTEMAE HOSPITAL   (Japan)

^e Matsumoto Hospital   (Japan)

^f Immuno Biological Laboratories Co Ltd   (Japan)

Author keywords

Ballooning hepatocyte; Liver fibrosis; Mac 2bp 90K; N glycan; NASH NAFLD

Indexed keywords

BIOLOGICAL MARKER; CASPASE; CYTOKERATIN 18; GALECTIN 3; MAC 2 BINDING PROTEIN; UNCLASSIFIED DRUG; FUCOSE; MEMBRANE PROTEIN; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUCOSYLATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; BLOOD; CASE CONTROL STUDY; CELL LINE; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS;

ANTIGENS, NEOPLASM; BIOMARKERS; CASE-CONTROL STUDIES; CELL LINE; FEMALE; FUCOSE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS;

EID: 84885947103     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200137     Document Type: Article

References (40)

1. Ford, E. S., Giles, W. H., Dietz, W. H., Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J. Am. Med. Assoc. 2002, 287, 356-359.
2. Bugianesi, E., Leone, N., Vanni, E., Marchesini, G. et al., Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123, 134-140.
3. Wanless, I. R., Lentz, J. S., Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12, 1106-1110.
4. Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P. et al., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40, 1387-1395.
5. Angulo, P., Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346, 1221-1231.
6. Liou, I., Kowdley, K. V., Natural history of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2006, 40(Suppl 1), S11-S16.
7. Ohtsubo, K., Marth, J. D., Glycosylation in cellular mechanisms of health and disease. Cell 2006, 126, 855-867.
8. Callewaert, N., Van Vlierberghe, H., Van Hecke, A., Laroy, W. et al., Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med. 2004, 10, 429-434.
9. Ito, K., Kuno, A., Ikehara, Y., Sugiyama, M. et al., LecT-hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology 2012, 56, 1448-1456.
10. Miyoshi, E., Moriwaki, K., Nakagawa, T., Biological function of fucosylation in cancer biology. J. Biochem. 2008, 143, 725-729.
11. Wang, M., Long, R. E., Comunale, M. A., Junaidi, O. et al., Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1914-1921.
12. Okuyama, N., Ide, Y., Nakano, M., Nakagawa, T. et al., Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int. J. Cancer 2006, 118, 2803-2808.
13. Nakagawa, T., Uozumi, N., Nakano, M., Mizuno-Horikawa, Y. et al., Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J. Biol. Chem. 2006, 281, 29797-29806.
14. Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C. et al., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41, 1313-1321.
15. Brunt, E. M., Tiniakos, D. G., Histopathology of nonalcoholic fatty liver disease. World J. Gastroenterol. 2010, 16, 5286-5296.
16. Yoon, Y., Torok, N., Krueger, E., Oswald, B., McNiven, M. A., Ethanol-induced alterations of the microtubule cytoskeleton in hepatocytes. Am. J. Physiol. 1998, 274, G757-G766.
17. Xia, X., Demorrow, S., Francis, H., Glaser, S. et al., Cholangiocyte injury and ductopenic syndromes. Semin. Liver Dis. 2007, 27, 401-412.
18. Matteoni, C. A., Younossi, Z. M., Gramlich, T., Boparai, N. et al., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116, 1413-1419.
19. Grassadonia, A., Tinari, N., Iurisci, I., Piccolo, E. et al., 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj. J. 2004, 19, 551-556.
20. Inohara, H., Akahani, S., Koths, K., Raz, A., Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res. 1996, 56, 4530-4534.
21. Inohara, H., Akahani, S., Raz, A., Galectin-3 stimulates cell proliferation. Exp. Cell Res. 1998, 245, 294-302.
22. Matarrese, P., Fusco, O., Tinari, N., Natoli, C. et al., Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int. J. Cancer 2000, 85, 545-554.
23. Nangia-Makker, P., Honjo, Y., Sarvis, R., Akahani, S. et al., Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 2000, 156, 899-909.
24. Iacobini, C., Menini, S., Ricci, C., Blasetti Fantauzzi, C. et al., Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J. Hepatol. 2011, 54, 975-983.
25. Wieckowska, A., Zein, N. N., Yerian, L. M., Lopez, A. R. et al., In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44, 27-33.
26. Feldstein, A. E., Wieckowska, A., Lopez, A. R., Liu, Y. C. et al., Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50, 1072-1078.
27. Sasaki, T., Brakebusch, C., Engel, J., Timpl, R., Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J. 1998, 17, 1606-1613.
28. Artini, M., Natoli, C., Tinari, N., Costanzo, A. et al., Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J. Hepatol. 1996, 25, 212-217.
29. Cheung, K. J., Tilleman, K., Deforce, D., Colle, I., Van Vlierberghe, H., The HCV serum proteome: a search for fibrosis protein markers. J. Viral Hepat. 2009, 16, 418-429.
30. Palekar, N. A., Naus, R., Larson, S. P., Ward, J., Harrison, S. A., Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006, 26, 151-156.
31. Harrison, S. A., Oliver, D., Arnold, H. L., Gogia, S., Neuschwander-Tetri, B. A., Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008, 57, 1441-1447.
32. Chitturi, S., Abeygunasekera, S., Farrell, G. C., Holmes-Walker, J. et al., NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35, 373-379.
33. Fargion, S., Mattioli, M., Fracanzani, A. L., Sampietro, M. et al., Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2001, 96, 2448-2455.
34. Ratziu, V., Giral, P., Charlotte, F., Bruckert, E. et al., Liver fibrosis in overweight patients. Gastroenterology 2000, 118, 1117-1123.
35. Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E. et al., The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45, 846-854.
36. Sumida, Y., Yoneda, M., Hyogo, H., Yamaguchi, K. et al., A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J. Gastroenterol. 2011, 46, 257-268.
37. Iacovazzi, P. A., Cozzolongo, R., Lanzillotta, E., Frisullo, S. et al., Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in HCV chronic patients. Immunopharmacol. Immunotoxicol. 2008, 30, 687-700.
38. Przybylo, M., Martuszewska, D., Pochec, E., Hoja-Lukowicz, D., Litynska, A., Identification of proteins bearing beta1-6 branched N-glycans in human melanoma cell lines from different progression stages by tandem mass spectrometry analysis. Biochim. Biophys. Acta 2007, 1770, 1427-1435.
39. Nonaka, M., Ma, B. Y., Imaeda, H., Kawabe, K. et al., Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J. Biol. Chem. 2011, 286, 22403-22413.
40. Nakagawa, T., Moriwaki, K., Terao, N., Miyamoto, Y. et al., Analysis of polarized secretion of fucosylated alpha-fetoprotein in HepG2 cells. J. Proteome Res. 2012.